Search

  1. ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer

    Press release

    … cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced its support … Since its inception in 2008, led by EURORDIS-Rare Diseases Europe and its Council of National Alliances, thousands of … common. LCA 10 leads to early loss of vision causing most people to lose their sight in the first few years of life. To …

  4. ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10

    Press release

    … six adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. … field stimulus testing (FST), ocular instability (OCI), optical coherence tomography (OCT), and pupillary light … global trial to be conducted at sites in North America and Europe with significant expertise in genetic retinal disease. …

  5. ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3

    Press release

    … Artur Cideciyan, Ph.D., professeur de recherche en ophtalmologie à l’Institut Scheie Eye de l’Université de … Vision Test ( BRVT) et le traitement précoce de la rétinopathie diabétique (ETDRS). À trois mois de traitement, … de 30 à 40 patients atteints d’ACL10 liée à une ou deux copies de la mutation p.Cys998X et pourrait être renouvelé en …

  7. ProQR to Present at EuroTIDES Conference

    Press release

    … cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced a … Vienna, Austria. The presentation titled “IPRP UPLC Method Optimization for the Separation of Short- and Longmer … and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing …

  8. ProQR Announces Pricing of Initial Public Offering

    Press release

    LEIDEN, Netherlands, Sept. 18, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics today announced the pricing of its initial public offering of 7,500,000 ordinary shares at an initial public offering price of $13.00 per ordinary share.

  10. ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

    Press release

    … diseases, today announced upcoming presentations at the European Cystic Fibrosis Society (ECFS) conference and the … and a poster presentation on eluforsen during the ECFS: European Cystic Fibrosis Society Conference to be held on … Eluforsen is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a …